"New molecular entities" for PD probably will not be anymore than palliatives, if the molecules are small. What we need is replacement of dying cells and/or enhancement of activity in any affected cells specific to the dopamine pump in the small areas of the brain. The first is "supergigantic micromolecular", or whole cell replacements.The second is a concentration of investigation of the "micro-midworld" where we are using cellular mechanism studies to repair the dopamine pump as it is being destroyed. This therapy is that of "very large to small peptides range" (sorta like cell growth factors).
WE need to get a grip on genetic abberations and how we can alter or manipulate them to perform whatever actions result in normal Dopaminergic functioning.
10 years, eh? Lets hope it's no more than like 20 or so.